CORT

Corcept Therapeutics Inc. is a pharmaceutical company focused on the discovery and development of medications to treat severe metabolic, oncologic, and psychiatric disorders by modulating the effects of cortisol. Headquartered in Menlo Park, California, the company's lead product is Korlym (mifepristone), approved for treating Cushing's syndrome, a rare disease caused by excess cortisol. Corcept has a pipeline of selective cortisol modulators in development for various conditions including ovarian cancer, prostate cancer, and antipsychotic-induced weight gain. The company holds extensive intellectual property around cortisol modulation therapies.